Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Anxiety/Depression and Asthma
Phase Not Applicable
Enrollment 256
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to explore the impact of anxiety/depression on the efficacy of asthma controller medications and to develop a risk prediction model for asthma acute exacerbations in patients with asthma. It will also analyze the association between anxiety/depression severity and asthma severity. The main questions it aims to answer are: Does anxiety/depression affect the therapeutic effect of asthma controller medications (e.g., asthma control level)? Can a reliable risk prediction model for asthma acute exacerbations be established based on anxiety/depression and other relevant factors? Researchers will conduct a prospective observational study to collect and analyze data from participants, without additional interventions beyond standard clinical care, to explore the above research questions. Participants will: Complete baseline assessments, including demographic information collection, medical history review, lung function tests, anxiety/depression evaluations (via GAD-7 and PHQ-9 scales), and provide biological samples (induced sputum, feces, blood) Undergo follow-up visits at 3, 6, 12, 18, and 24 months after baseline Report asthma symptoms, acute exacerbation events, and cooperate with required clinical checkups during follow-up

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: No intervention measures — No intervention measures

Primary Outcomes

  • Acute asthma attack (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-12-01
Completion: 2027-12-30
Eligibility
Age: 14 Years and older
Sex: ALL
Volunteers: false
Enrollment: 256 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Xiangya Hospital of Central South University
Contact Information
Study Contact:
Yuanyuan Li, Doctor
+8619976695523
Leeround@csu.edu.cn
Xiangya Hospital Central South University
Interventions
  • Other: No intervention measures — No intervention measures
Study Locations (1 sites)
Xiangya Hospital Central South University, Changsha, Hunan 410008 China
Eligibility Criteria
Inclusion Criteria: * Diagnosis of asthma according to the Global Initiative for Asthma (GINA) 2024 criteria. * Male or female patients aged 14 years or older. * Complete clinical data available. * Newly diagnosed asthma or stable asthma. * Receiving asthma controller medication. Exclusion Criteria: * History of major lung diseases other than asthma, congestive heart failure, cor pulmonale, or recent cardiac or thoracic surgery. * Incomplete medical records. * Cognitive impairment or inability to complete psychological scale assessments. * Clinically diagnosed acute or chronic mental disorders, such as bipolar disorder or schizophrenia. * Current use of antidepressant or anti-anxiety medications. * Pregnancy or lactation.
Conditions Asthma
Phase PHASE1
Enrollment 24
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to compare how two different formulations of the study medicine (GSK5784283) move through the body over time (pharmacokinetic \[PK\] study) in healthy adults. The aim of the study is to see how the body processes GSK5784283 and determine if the study medicine is safe, how well it is tolerated by the body and if the study medicines being tested work in the body in the same way.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: GSK5784283 — GSK5784283 will be administered.

Primary Outcomes

  • Maximum Observed Concentration (Cmax) of GSK5784283 Serum Samples (Pre-dose and up to 253 days post dose)
  • Area Under the Curve from Zero up to 253 Days [AUC(0-253 d)] of GSK5784283 Serum Samples (Pre-dose and up to 253 days post dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-07-17
Completion: 2027-04-26
Eligibility
Age: 18 Years – 60 Years
Sex: ALL
Volunteers: true
Enrollment: 24 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Principal Investigators:
  • GSK Clinical Trials (STUDY_DIRECTOR) - GlaxoSmithKline
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Interventions
  • Drug: GSK5784283 — GSK5784283 will be administered.
Study Locations (1 sites)
GSK Investigational Site, Austin, Texas 78744 United States
Eligibility Criteria
Inclusion Criteria: * Participants who are healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECG. * Body weight greater than or equal (\>=) 50 kilogram (kg) (110 pounds \[lbs\]) and body mass index within the range 19 to 30 kilogram per meter square (kg/m\^2) (inclusive). * A female participant is eligible to participate if she is a participant of non-childbearing potential (PONCBP) as specified in the protocol. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. Exclusion Criteria: * Hypersensitivity- Participants with allergy/intolerance to any biologic therapy or any of the known excipients used in products administered subcutaneously * History or presence of any clinically significant medical condition capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data. * Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs during screening period which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study. * Live vaccine(s) within 1 month prior to screening or plans to receive such vaccines during the clinical study. * Treatment with biologic agents (such as monoclonal antibodies including marketed drugs) within 3 months or 5 half-lives (whichever is longer) prior to study intervention administration. * Current smokers (tobacco and/or marijuana) or former smokers with a smoking history \>10 pack-years and participants using vaping products, including electronic cigarettes. * Regular alcohol consumption that exceeds the limits specified in the protocol * Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates participation in the clinical study. * The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine-read or manually over-read \>450 millisecond (msec).
Conditions Asthma in Children
Phase Not Applicable
Enrollment 340
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

Children with long-term lung diseases like asthma need better techniques for diagnosis and monitoring of their disease. With better monitoring, it is anticipated that children and their carers will be able to manage their disease better, and be able to spot a deterioration in their condition sooner, leading to earlier intervention, for example to prevent an asthma attack. However, current devices which could be used at home are either too costly, require machines that are impractically large, or require specific breathing maneuvers which are unpopular with patients, or which are difficult for younger children to perform. There is a need for better devices. The N-Tidal C is a CE Marked medical device which measures exhaled carbon dioxide levels accurately. Early work in its use in adult diseases such as Chronic Obstructive Pulmonary Disease indicates that the device can detect altered lung function associated with disease. This device has several attractive properties for children - it is small, easy to use, and does not require specific breathing maneuvers - just normal breathing. Based on data from a small feasibility study, the study investigators believe that this device will be useful in children. Young children can use it with minimal instruction. Parents and children have reported that it is easy to use. The investigators do not yet have sufficient feasibility information required to plan a larger study, such as deciding how many children the future study will need to recruit, or knowing how well the measurements made with the device agree with standard lung function tests. In this work, the investigators are conducting a feasibility study to determine the number of children needed for a larger trial and to explore how well the N-Tidal C device measurements compare with standard lung function tests. Data from this study will be used to plan future larger studies of the device in children with respiratory diseases.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: N-Tidal — Capnometry

Primary Outcomes

  • 1. Percentage (%) of patients approached who enrol in the study (At recruitment. Participants will be given at least 24 hours to consider whether they would like to enrol in the study. If they have not enrolled in the study within 7 completed days, they will have been approached but not enrolled.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2024-07-15
Completion: 2026-12-31
Eligibility
Age: 5 Years – 15 Years
Sex: ALL
Volunteers: true
Enrollment: 340 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Nottingham
Collaborators: Nottingham University Hospitals NHS Trust
Contact Information
Study Contact:
Andrew P Prayle, BMBS
+44 (0) 115 9249924
andrew.prayle@nottingham.ac.uk
Andrew P Prayle, BMBS
+44 115 8230623
andrew.prayle@nottingham.ac.uk
Nottingham University Hospitals NHS Trust
Andrew P Prayle
07764758506
andrew.prayle@nottingham.ac.uk
Nottingham University Hospitals NHS Trust
Interventions
  • Diagnostic Test: N-Tidal — Capnometry
Study Locations (2 sites)
Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire NG7 2UH United Kingdom
Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire NG7 2UH United Kingdom
Eligibility Criteria
Workstream 1 inclusion criteria i) Aged 5 years or older, and less than 15 years plus 32 weeks of age ii) Participant has presented to hospital with acute wheeze, bronchospasm or asthma iii) Participant is not critically ill and is able to breathe into a mouthpiece for 90seconds. Workstream 2 inclusion criteria i) Participant 5 years or older, and less than 16 years of age. ii) Participant is due to have routine lung function testing. Exclusion criteria i) Life threatening respiratory difficulties (defined as cyanosis, oxygen saturations less than 92% despite oxygen supplementation, silent chest on auscultation, poor respiratory effort, fatigue or exhaustion, agitation or reduced level of consciousness) ii) Participation in another research project whose protocol prevents participation in this project.
Conditions Asthma, Respiratory Tract Infections, Ga...
Phase PHASE3
Enrollment 2000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The overall aim of the study is to develop a nutritional preventive fish oil supplementation strategy in pregnancy for early childhood asthma/persistent wheeze during the first three years of life as we hypothesize that both supplementations in higher doses than recommended could reduce the risk of disease development.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Quadruple

Interventions / Regimen

  • Dietary Supplement: n-3 fatty acid — Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
  • Other: Rape seed oil — Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery

Primary Outcomes

  • Early childhood asthma/persistent wheeze age 0-3 years (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-12-20
Completion: 2033-03
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: true
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Professor Klaus Bønnelykke
Principal Investigators:
  • Bo Chawes, PhD (PRINCIPAL_INVESTIGATOR) - Copenhagen Studies on Asthma in Childhood
  • Klaus Bønnelykke, PhD (PRINCIPAL_INVESTIGATOR) - Copenhagen Studies on Asthma in Childhood
Contact Information
Study Contact:
Klaus Bønnelykke, PhD
+45 38677360
kb@copsac.com
Ulrik Ralfkiaer, PhD
+45 38674164
administration@dbac.dk
Klaus Bønnelykke, PhD
+45 38677360
kb@copsac.com
Copenhagen University Hospital of Copenhagen
Interventions
  • Dietary Supplement: n-3 fatty acid — Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
  • Other: Rape seed oil — Oral intake of 4 capsules per day from week 22-26 in pregnancy to 1 week after delivery
Study Locations (1 sites)
Copenhagen University Hospital of Copenhagen, Gentofte Municipality, DK-2820 Denmark
Eligibility Criteria
* Pregnant Danish women before week 26 with blood levels of EPA+DHA below 4.7% of total fatty acids * No planned use of fish oil supplementations * No endocrine-, heart-, kidney- or auto-immune disorders * No disorders requiring treatment with blood thinning medication

Severe Asthma Network Italy

NCT06625216
Recruiting
Conditions Severe Asthma
Phase Not Applicable
Enrollment 5000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this registry is collecting data of severe asthma patients, recruited by specialized centers, in a real life setting, homogeneously placed on a database management system to follow them over the time. The information recorded will provide: 1. The collection of homogeneous clinical, functional and biologic data of patients with severe asthma in a real life setting. 2. The evaluation of adherence to treatment in real life. 3. The clinical eligibility of patients treated with biologics. 4. The evaluation of patients' clinical response to each treatment. 5. The monitoring of tolerability and safety. 6. The long-term follow up of patients with severe asthma.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
  • Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
  • Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
  • Analyzing epidemiological and clinical characteristics of severe asthmatics from SANI registry. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
  • Collecting functional data of severe asthmatics from SANI registry. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
  • Collecting functional data of severe asthmatics from SANI registry. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
  • Assessing inflammatory markers in order to characterize asthma endotypes. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
  • Assessing inflammatory markers in order to characterize asthma endotypes. (through study completion (the length of the follow up for each patient is scheduled for 10 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2017-02-17
Completion: 2037-02-17
Eligibility
Age: 13 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Società Italiana di Allergologia, Asma e Immunologia Clinica
Collaborators: Societa Italiana di Pneumologia
Principal Investigators:
  • Enrico Marco Heffler, MD, PhD (STUDY_CHAIR) - Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
Contact Information
Study Contact:
Enrico Marco Heffler, MD, PhD
0282241
enrico.heffler@hunimed.eu
Concetta Sirena
3420790871
concetta.sirena@infomed-online.it
Enrico Marco Heffler, MD, PhD
0282241
enrico.heffler@hunimed.eu
Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy
Interventions
N/A
Study Locations (1 sites)
Personalized Medicine, Asthma and Allergy - IRCCS Humanitas Research Hospital, Rozzano, Italy, Rozzano, Milano 20089 Italy
Eligibility Criteria
Inclusion Criteria: 1. signed informed consent and privacy disclaimer; 2. age \> 12 years; 3. diagnosis of severe asthma according to the ERS/ATS criteria: 1. During treatment with: * High-dose ICS + at least one addistional controller (LABA, montelukast, or theophylline) or * Oral corticosteroids \>6 months/year 2. at least one of the following occurs or would occur if treatment would be reduced: * ACT \<20 or ACQ\>1.5 * At least 2 exacerbations in the last 12 months * At least 1 exacerbation treated in hospital or requiring mechanical ventilation in the last 12 months * FEV1 \<80% (if FEV1/FVC below the lower limit of normal) Exclusion Criteria have not been considered in order to have a realistic view of severe asthma in real life.
Conditions Chronic Obstructive Pulmonary Disease (C...
Phase Not Applicable
Enrollment 859
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The investigators aim to make it easier to find people with undiagnosed long-term lung health problems (such as asthma, and chronic obstructive pulmonary disease, COPD, collectively called 'Chronic Respiratory Diseases', CRDs) living in Brasil. Because people with undiagnosed CRDs often have other medical problems too, such as heart problems, high blood pressure and diabetes (collectively called 'Long Term Conditions', LTC), the investigators will look for undiagnosed CRD in people with LTC when they are attending appointments at local health centres in the cities of Sao Carlos and Sao Paulo. To look for undiagnosed CRDs the investigators will use two questionnaire-based methods called 'COLA' and 'SBQ'. These are quick and simple to do. All participants will also have tests of their lung function completed including spirometry and Fractional Exhaled Nitric Oxide so that the investigators can make a definite diagnosis of CRDs. When the study is complete, the investigators will examine how well the COLA and SBQ questionnaires perform in identifying people with a definite diagnosis of CRD. In total, the investigators aim to recruit 859 people.

Design

Study type: Observational Observational model: Case Only Time perspective: Cross Sectional

Primary Outcomes

  • Discriminative accuracy of the 'COLA' case-finding questionnaire for diagnosis of abnormal spirometry (Baseline: all assessments are conducted at one visit and the discriminative accuracy of the 'COLA' case-finding questionnaire for diagnosis of abnormal spirometry will use the COLA and spirometry data from the single visit.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-07-01
Completion: 2027-07
Eligibility
Age: 30 Years and older
Sex: ALL
Volunteers: false
Enrollment: 859 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University College, London
Collaborators: Universidade Federal de Sao Carlos
Principal Investigators:
  • John R Hurst, PhD FRCP (PRINCIPAL_INVESTIGATOR) - University College London Hospitals
  • Renata G Mendes, DFisio/ PPGFt (PRINCIPAL_INVESTIGATOR) - Federal University of Sao Carlos (UFScar), Brasil
Contact Information
Study Contact:
Trial Manager
(+5516) 99992-4777
vivianecastello@ufscar.br
Trial Manager
vivianecastello@ufscar.br
Multiple primary care sites
Trial Manager
vivianecastello@ufscar.br
Multiple primary care sites
Interventions
N/A
Study Locations (2 sites)
Multiple primary care sites, São Carlos, São Paulo Brazil
Multiple primary care sites, São Paulo, São Paulo Brazil
Eligibility Criteria
Inclusion Criteria: Attending primary health care services in Brasil. Diagnosed with one or more existing, non-respiratory long-term conditions such as cardiovascular disease, diabetes or hypertension. Exclusion Criteria: Clinically unstable in the past month (defined as worsening symptoms requiring emergency care or hospitalization). Current pregnancy. Active pulmonary tuberculosis or undergoing treatment for pulmonary tuberculosis. Current acute respiratory infection. Cognitive impairment that prevents understanding of the case-finding questionnaire, defined as MMSE score ≤20. Contraindications to spirometry. Declines to participate in the study.
Conditions Major Depressive Disorder (MDD), Depress...
Phase PHASE2
Enrollment 153
Locations 28 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: ACP-211 — ACP-211 monotherapy
  • Drug: Placebo — Placebo control

Primary Outcomes

  • Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score at Day 28 (Baseline and Day 28)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-11-14
Completion: 2027-09
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 153 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: ACADIA Pharmaceuticals Inc.
Contact Information
Study Contact:
Sandy Filosi
+1(609) 250-6920
sfilosi@ACADIA-Pharm.com
Lori Lykens
+1(609) 250-6917
lori.lykens@acadia-pharm.com
Interventions
  • Drug: ACP-211 — ACP-211 monotherapy
  • Drug: Placebo — Placebo control
Study Locations (28 sites)
University of Alabama at Birmingham, Birmingham, Alabama 35294 United States
Inland Psychiatric Medical Group, Chino, California 91710 United States
Behavioral Research Specialists, LLC, Glendale, California 91107 United States
Kadima Neuropsychiatry Institute, La Jolla, California 92037 United States
PNS Clinical Research LLC dba ATP Clinical Research, Orange, California 92866 United States
Focus Clinical Research, LLC d/b/a Alliance Clinical West Hills, West Hills, California 91307 United States
Mountain View Clinical Research, Denver, Colorado 80209 United States
New Access Research and Medical Services, Inc., Fort Myers, Florida 33901 United States
The Medici Medical Research, Hollywood, Florida 33021 United States
Sandhill Research, LLC/DBA Accel Research Sites, Largo, Florida 33777 United States
Eligibility Criteria
Inclusion Criteria: * Adults ≥18 and ≤65 years of age * Provides written informed consent * Clinical diagnosis of MDD * History of inadequate response to at least two antidepressants, with at least one inadequate response documented during the current episode * Currently treated with an approved antidepressant at a stable dose prior to Screening * MADRS total score ≥28, CGI-S score ≥4 , and QIDS-SR16 score ≥16 at Screening and Baseline * Females of childbearing potential must have a negative pregnancy test and agree to use acceptable contraception; males must agree to use barrier protection and refrain from sperm donation Exclusion Criteria: * Current diagnosis of certain personality disorders or persistent depressive disorder * Recent substance use disorders, excluding caffeine or nicotine * Active suicidal risk or recent suicidal attempt * History of schizophrenia, psychotic disorders, bipolar disorder, or MDD with psychotic features * Current treatment requirement for PTSD, acute stress disorder, panic disorder, or OCD * History of neuroleptic malignant syndrome, serotonin syndrome, or epilepsy (except single febrile seizure in infancy) * Allergy or sensitivity to ketamine or esketamine * Significant cardiovascular disease * Positive history of hepatitis B, hepatitis C, or HIV infection * Unstable diabetes or uncontrolled medical conditions * Positive urine drug test for an illicit drug or cannabis * Received neuromodulation therapies (ECT, TMS, VNS, DBS) in the current depressive episode * Recent initiation or change in psychotherapy Additional inclusion/exclusion criteria apply. Participants will be evaluated at Screening to ensure that all criteria for study participation are met.
Conditions Episodic Migraine, Chronic Migraine
Phase Not Applicable
Enrollment 120
Locations 1 sites
Compensation Compensation or reimbursement is mentioned in the public study record; confirm details with the study team.
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this clinical study is to better understand the function of the autonomic nervous system in patients with migraine. We aim to understand whether the autonomic functions change depending on the migraine status (i.e. whether they are between or during attacks) and whether the CGRP monoclonal antibody (mAb) class of drugs affects the autonomic functions. The aim is not to investigate the effect of CGRP-mAb on migraine frequency. Calcitonin gene-related peptide (CGRP) is a neurotransmitter in the nervous system that plays an essential role in the development of migraine headache. Monoclonal antibodies can block the function of this messenger substance. Several studies have shown that this blockade leads to a reduction in the frequency of migraine. In addition to its role in migraine, CGRP also acts on the blood vessels and the autonomic nervous system. The autonomic nervous system is responsible for everything we have no control over in our body. This includes everything from heart rate and blood pressure to our digestion.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Drug: Erenumab — anti-CGRP-receptor monoclonal anti-body
  • Drug: Galcanezumab — anti-CGRP-ligand monoclonal anti-body
  • Drug: Fremanezumab — anti-CGRP-ligand monoclonal anti-body

Primary Outcomes

  • Change from Day 0 Cardiovagal Autonomic Dysfunction (CAD) at 5 months (Day 0, Month 5 (EOS))
  • Change from Days 1-31 Cardiovagal Autonomic Dysfunction (CAD) at 5 months (Days 1-31, Month 5 (EOS))
  • Change from Days 0 Cardiovagal Autonomic Dysfunction (CAD) at Days 1-31 (Day 0, Days 1-31)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-10-01
Completion: 2026-12
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of Vienna
Principal Investigators:
  • Christian Wöber, Prof. MD (PRINCIPAL_INVESTIGATOR) - Medical University of Vienna
Contact Information
Study Contact:
Antun R Pavelic, MD
+43 (0)1 40400 - 31170
antun.pavelic@meduniwien.ac.at
Antun R Pavelic, MD
+43 (0)1 40400 - 31170
antun.pavelic@meduniwien.ac.at
Medical University of Vienna
Interventions
  • Drug: Erenumab — anti-CGRP-receptor monoclonal anti-body
  • Drug: Galcanezumab — anti-CGRP-ligand monoclonal anti-body
  • Drug: Fremanezumab — anti-CGRP-ligand monoclonal anti-body
Study Locations (1 sites)
Medical University of Vienna, Vienna, 1090 Austria
Eligibility Criteria
Inclusion Criteria: * Chronic migraine according to ICHD-3 * Episodic migraine without aura or with aura according to ICHD-3 * Unsuccessful treatment with 3 or more established prophylactic drugs * Medicine costs are covered by health insurance * Healthy controls must be free from any diagnosed chronic disease or acute infection requiring medication Exclusion Criteria: * Pregnancy and lactation * Neurosurgical interventions performed within the last 12 months * Coronary bypass surgery or revascularization procedures performed within the last 12 months * History of transient ischemic attacks (TIA), stroke, stable or unstable angina pectoris, myocardial infarction or uncontrolled hypertension * Known hypersensitivity to therapy with an anti-CGRP Antibodies * History of a disorder (other than migraine) that may affect the results of autonomic tests * Healthy controls must have no personal or family history of migraine
Conditions Post Traumatic Stress Disorder, Post Par...
Phase Not Applicable
Enrollment 420
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to learn whether early postpartum screening tools can predict the development of childbirth-related post-traumatic stress symptoms in individuals who undergo unplanned cesarean delivery. The main questions it aims to answer are: * Do scores on the Peritraumatic Distress Inventory (PDI) collected 24-48 hours after delivery predict childbirth-related PTSD symptoms at 6 weeks postpartum? * Do scores on the City Birth Trauma Scale - Short Form (CityBiTS-SF) collected 24-48 hours after delivery predict childbirth-related PTSD symptoms at 6 weeks postpartum? Participants will: * Complete questionnaires within 24-48 hours after delivery, including the PDI, CityBiTS-SF, and Edinburgh Postnatal Depression Scale (EPDS). * Complete follow-up questionnaires at 6 weeks and 3 months postpartum, including measures of PTSD symptoms (PTSD Checklist for DSM-5, PCL-5) and depressive symptoms. Researchers will evaluate whether early screening scores are associated with later symptoms of childbirth-related PTSD and postpartum depression, and will assess the feasibility and acceptability of implementing routine inpatient screening for psychological birth trauma.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Postpartum Psychological Screening — Participants complete validated screening questionnaires 24-48 hours postpartum, including the Peritraumatic Distress Inventory, City Birth Trauma Scale - Short Form, and Edinburgh Postnatal Depression Scale (EPDS). Follow-up surveys at 6 weeks and 3 months postpartum include the PTSD Checklist for DSM-5, EPDS, and City Birth Trauma Scale - Long Form

Primary Outcomes

  • Sensitivity of the Peritraumatic Distress Inventory (PDI ≥15) for Predicting Childbirth-Related PTSD Symptoms at 6 Weeks Postpartum (6 weeks postpartum)
  • Sensitivity of the City Birth Trauma Scale - Short Form (CityBiTS-SF ≥4) for Predicting Childbirth-Related PTSD Symptoms at 6 Weeks Postpartum (6 weeks postpartum)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-08
Completion: 2028-04
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 420 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of British Columbia
Collaborators: Women's Health Research Institute of British Columbia
Contact Information
Study Contact:
Katherine Seligman, MD
604-875-2158
katie.seligman@cw.bc.ca
Katherine Seligman, MD
6048752158
katie.seligman@cw.bc.ca
BC Women's Hospital and Health Centre
Interventions
  • Other: Postpartum Psychological Screening — Participants complete validated screening questionnaires 24-48 hours postpartum, including the Peritraumatic Distress Inventory, City Birth Trauma Scale - Short Form, and Edinburgh Postnatal Depression Scale (EPDS). Follow-up surveys at 6 weeks and 3 months postpartum include the PTSD Checklist for DSM-5, EPDS, and City Birth Trauma Scale - Long Form
Study Locations (1 sites)
BC Women's Hospital and Health Centre, Vancouver, British Columbia V6H 3N1 Canada
Eligibility Criteria
Inclusion Criteria: * Age ≥19 years * Underwent unplanned cesarean delivery * Able to provide informed consent * Able to read and understand English questionnaires Exclusion Criteria: * Fetal or neonatal demise * Unable to complete study questionnaires or provide informed consent
Conditions Depressed Mood
Phase Not Applicable
Enrollment 5000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study will evaluate the feasibility and clinical utility of developing predictive models of treatment response for patients with depressed mood using multimodal clinical data collected in real-world clinical settings. The study will examine outcomes among patients treated with interventions including esketamine, conventional transcranial magnetic stimulation (TMS), or Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT). Retrospective clinical and research data from existing databases may also be incorporated, when available and authorized, to support model development and validation. The goal is to assess whether integrated clinical datasets can be used to support the development of predictive tools that may inform personalized treatment selection in depression.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Patient Health Questionnaire 9-item (PHQ-9) (Pre-treatment, Post-treatment, 2 weeks posttreatment, and Monthly post-treatment for 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-25
Completion: 2037-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Salma Health, Inc.
Collaborators: Center for Neurohealth, Inc
Contact Information
Study Contact:
Clinical Research Coordinator
858-294-0161
research@salmahealth.com
Salma Health
Clinical Research Coordinator
858-294-0161
research@salmahealth.com
Salma Health
Interventions
N/A
Study Locations (2 sites)
Salma Health, La Jolla, California 92037 United States
Salma Health, Laguna Hills, California 92653 United States
Eligibility Criteria
Inclusion Criteria: * Adults (≥18 years) of any gender identity presenting for care with a depressed mood. * Prescribed treatment with esketamine, conventional TMS, or SAINT as part of standard clinical care. * Able to provide informed consent and comply with all study requirements. Exclusion Criteria: * Any condition deemed by the investigator to preclude safe participation in study assessments.
Conditions Depression, Unipolar, Depression Moderat...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

The present project aims to assess the neurocognitive impact of a two-week once-a-day regimen of intermittent theta burst stimulation (iTBS) compared to sham iTBS, when targeting the left dorsolateral prefrontal cortex (LDLPFC) in clinically depressed outpatients. The study investigates the relationships between changes in cerebral measures and cognitive performance on an N-back task in relation to the antidepressive effect following iTBS.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Triple

Interventions / Regimen

  • Device: Intermittent Theta Burst Stimulation — Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).

Primary Outcomes

  • Data from magnetic resonance imaging - white matter integrity (Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days)
  • Data from magnetic resonance imaging - cortical thickness (Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days)
  • Data from magnetic resonance imaging - cerebral activity (Change from the pretest to the posttest after 10 treatments with iTBS, an average of 15 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-02-12
Completion: 2029-02-12
Eligibility
Age: 22 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital of North Norway
Collaborators: UiT The Arctic University of Norway
Contact Information
Study Contact:
Per M Aslaksen, PhD
77649234
per.aslaksen@unn.no
Marte C Ørbo, PhD
77645333
marte.c.orbo@uit.no
Ole Grønli, MD, PhD
ole.k.gronli@unn.no
University Hospital North Norway
Interventions
  • Device: Intermittent Theta Burst Stimulation — Intermittent Theta Burst Stimulation will be delivered with 120% of resting motor threshold with triplet 50 Hz bursts repeated at 5 Hz; 2 seconds on and 8 s off, 600 pulses per session with a total duration of 3 min 9 s. Treatment will be provided for 10 days for two consecutive weeks (except Saturdays and Sundays).
Study Locations (1 sites)
University Hospital North Norway, Tromsø, 9038 Norway
Eligibility Criteria
Inclusion criteria: * Patients must meet the diagnostic criteria of at least a moderate depression * The duration of the current depressive episode must have lasted more than 2 weeks but less than 2 years * Drug therapy must have been stable for the last three weeks prior to the first treatment day with iTBS * Patients must volunteer to provide informed consent, be able to follow the treatment schedule and have a satisfactory safety screening for iTBS and MRI Exclusion criteria: * The current depressive episode is in the mild range * The current episode fulfills the criteria for a major depressive episode requiring inpatient treatment and/or electroconvulsive therapy, * The current depressive episode is clearly triggered by grief or a recent major stressful life event * Bipolar disorder * Borderline personality disorder * Psychotic symptoms * Alcohol or substance abuse/addiction in the last 6 months * Current eating disorders * Obsessive- compulsive disorders * Post-traumatic stress disorder * A life-time medical history of seizure * Neurological or neurosurgical pathologies * Cardiac or systemic disease * Metallic prosthetic material or foreign objects (pacemakers, prosthetic eye equipment, etc.) * Autism * Pregnancy * Currently using of antipsychotic medication or benzodiazepines - or any medication that interferes with motor threshold excitability
Conditions Systemic Lupus Erythematosus of Childhoo...
Phase NA
Enrollment 175
Locations 7 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-07
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to investigate the feasibility and effectiveness of a cognitive behavioral coping skills program, Treatment and Education Approach for Childhood-onset Lupus (TEACH), for youth with cSLE when integrated into medical care. This TEACH program aims to teach participants skills in order to cope with fatigue, pain, and depressive symptoms--symptoms that commonly affect adolescents and young adults with lupus.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: TEACH — TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.

Primary Outcomes

  • Depressive symptoms, as measured by the Children's Depression Inventory-2 (CDI-2) and Beck Depression Inventory-II (BDI-II) (primary) (T1 (baseline), T2 (8 weeks), T3 (20 weeks), T4 (32 weeks), T5 (44 weeks), T6 (56 weeks))
  • Depressive symptoms, as measured by the Patient Health Questionnaire - 9 (PHQ-9) (primary) (T1 (baseline), T2 (8 weeks), T3 (20 weeks), T4 (32 weeks), T5 (44 weeks), T6 (56 weeks))
  • Fatigue, as measured by the PROMIS Fatigue short form (secondary) (T1 (baseline), T2 (8 weeks), T3 (20 weeks), T4 (32 weeks), T5 (44 weeks), T6 (56 weeks))
  • Pain, as measured by the Pain Visual Analog Scale (VAS) (T1 (baseline), T2 (8 weeks), T3 (20 weeks), T4 (32 weeks), T5 (44 weeks), T6 (56 weeks))
  • Pain, as measured by PROMIS Pain Interference Short Form (T1 (baseline), T2 (8 weeks), T3 (20 weeks), T4 (32 weeks), T5 (44 weeks), T6 (56 weeks))
  • Psychological stress, as measured by the PROMIS psychological stress experience measure (T1 (baseline), T2 (8 weeks))
  • Cognitive functioning, as measured by the PROMIS Cognitive Function Short Form for Adults and the PROMIS Cognitive Function Short Form for Pediatrics (T1 (baseline), T2 (8 weeks), T3 (20 weeks), T4 (32 weeks), T5 (44 weeks), T6 (56 weeks))
  • Quality of life, as measured by the Pediatric Quality of Life (PedsQL) Generic Core (T1 (baseline), T2 (8 weeks), T3 (20 weeks), T4 (32 weeks), T5 (44 weeks), T6 (56 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-09-12
Completion: 2027-09-30
Eligibility
Age: 12 Years – 22 Years
Sex: ALL
Volunteers: false
Enrollment: 175 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Michigan State University
Collaborators: United States Department of Defense, The Hospital for Sick Children, Seattle Children's Hospital, Children's Hospital Medical Center, Cincinnati, Tulane University, University of Alabama at Birmingham, Helen DeVos Children's Hospital, Montefiore Medical Center
Principal Investigators:
  • Natoshia R Cunningham, PhD (PRINCIPAL_INVESTIGATOR) - Michigan State University
  • Andrea Knight, MD, MSCE (PRINCIPAL_INVESTIGATOR) - The Hospital for Sick Children
Contact Information
Study Contact:
Jocelyn S Zuckerman, BA
9785051866
zucker32@msu.edu
Natoshia R Cunningham, PhD
845-662-6198
natoshia@msu.edu
Livie Timmerman
205-638-9483
lhuie@uabmc.edu
University of Alabama Birmingham Hospital
Interventions
  • Behavioral: TEACH — TEACH is a cognitive behavioral coping skills program. It consists of six one-hour weekly sessions that are conducted either in-person or remotely.
Study Locations (7 sites)
University of Alabama Birmingham Hospital, Birmingham, Alabama 35233 United States
Children's Hospital of New Orleans/ Tulane University, New Orleans, Louisiana 70118 United States
Helen Devos Children's Hospital, Grand Rapids, Michigan 49503 United States
Montefiore Medical Center, The Bronx, New York 10467 United States
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229 United States
Seattle Children's Hospital, Seattle, Washington 98105 United States
The Hospital for Sick Children, Toronto, Ontario ON M5G 1E8 Canada
Eligibility Criteria
Inclusion Criteria: * 1\) be diagnosed with cSLE, meeting the revised American College of Rheumatology Classification Criteria for SLE by age 18 years * 2\) be between the ages of 12 and 22 years * 3\) in recognition of the heterogeneity of cSLE symptoms, have elevations in fatigue (i.e., T scores ≥60; or at least moderate symptoms, on the PROMIS measure) OR depressive symptoms (≥5 on the PHQ-9, T Score ≥ 60 on the BDI or CDI II ), OR pain (i.e., average pain ≥3 out of 10 on the Pain VAS) * 4\) have English language proficiency (their primary caregiver can have English or Spanish language proficiency for the child to enroll) * 5\) those under age 18 years (US), or 16 years (Canada) must have a consenting caregiver Exclusion Criteria: * 1\) other chronic medical conditions (e.g., juvenile arthritis) * 2\) a documented developmental delay, severe cognitive impairment, or thought disorder * 3\) an untreated major psychiatric illness (e.g., bipolar disorder, psychosis, severe depression (PHQ9 score ≥21, BDI/CDI II \> 90) or active suicidal ideation (SI), based on the Pediatric Health Questionnaire (PHQ-9) items plus clinical interview; see Measures section)